Heterogeneous integration of silicon-fabricated solid microneedle sensors and CMOS circuitry

Information

  • Patent Grant
  • 11963796
  • Patent Number
    11,963,796
  • Date Filed
    Wednesday, June 16, 2021
    2 years ago
  • Date Issued
    Tuesday, April 23, 2024
    13 days ago
Abstract
A skin-adorned physiological or biochemical sensing device is disclosed herein. The device preferably comprises a first substrate and a second substrate. The first substrate comprises an array of solid microneedles designed to penetrate a biological interface to access a physiological fluid or tissue. Each microneedle is capable of electrical interface with the physiological fluid or tissue. The second substrate comprises integrated circuitry designed to transduce at least one signal produced by an electrophysiological or electrochemical reaction. A sensing device is formed that is capable of interpreting the signal arising from the electrophysiological or electrochemical reaction to ascertain the level of some physiological or biochemical entity.
Description
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

Not Applicable


BACKGROUND OF THE INVENTION
Field of the Invention

The present invention generally relates to sensors.


Description of the Related Art

The integration of silicon-fabricated microneedles with conventional silicon complementary metal-oxide semiconductor (“CMOS”) circuitry is of utmost importance in perpetuating the miniaturization efforts of body-worn medical devices. Despite the current state of semiconductor miniaturization and packaging, the creation of a heterogeneous system comprised of microneedle-based sensors and the CMOS circuitry required to transduce the signals generated by such devices has posed a formidable challenge to those aiming to create low-profile, highly-integrated body-worn sensors for the quantification of physiological or biochemical signals. Indeed, leveraging state-of-the-art semiconductor processing and packaging methods in conjunction with CMOS-based circuitry and recent developments in minimally-invasive silicon-based microneedle devices for physiological and biochemical sensing would enable the construction of a self-contained sensing system in a single package.


U.S. Pat. No. 8,506,529 for a Method and structure of monolithetically integrated microneedle biochip discloses a method and device using CMOS and MEMS fabrication techniques for making an integrated microneedle device with integrated circuits. Merely by way of example, the technology can be applied to bio and chemical sensing, and other bioMEMS applications. In some embodiments, the integrated circuits are completed using standard IC processes. For example, an array of microneedles are fabricated on top of the IC substrate followed by formation of micro fluidic channels in the substrate. On-chip integrated circuits enable real-time sensing and intelligent drug delivery.


U.S. Pat. No. 5,953,306 for a Micro needle probe apparatus having probes cantilevered over respective electronic circuits, moving medium memory device including same and method of making same discloses micro needle probe apparatus that includes a probe and its associated electronic circuit. The electronic circuit is formed in a substrate and includes at least one metal interconnection layer. The probe is cantilevered over the electronic circuit and is composed of a metal probe arm, a support post that anchors one end of the probe arm to the substrate, and a micro needle mounted adjacent the moveable end of the probe arm. The probe apparatus may be used as the read/write mechanism of the moving-medium type memory device.


U.S. Pat. No. 8,452,369 for a CMOS compatible microneedle structures discloses an electronic device for sensing and/or actuating, the electronic device comprising at least one microneedle (10) on a substrate (1), each of the microneedles (10) comprising at least one channel (7, 8) surrounded by an insulating layer (6).


Prior art solutions have been concerned with the integration of silicon-based microneedle arrays and CMOS circuitry as discrete devices populating a printed circuit board; in certain circumstances, these metallic wires are coated with a layer of metal salt, such as a silver wire functionalized on the surface with a layer of silver chloride. Such integration fails to minimize device footprint, especially in x-y dimensions, since device area constitutes the summation of the area of any discrete CMOS circuitry, microneedle sensor(s), and area devoted to interconnect between these two entities on said printed circuit board. Under such a design philosophy, efforts have largely been devoted to ultra-large scale integration of CMOS circuitry and the creation of CMOS systems-on-a-chip to minimize the number of discrete CMOS devices populating a sensing system. Likewise, recent efforts have been directed at reducing the number of components required to realize microneedle-mediated sensing via the integration of electrophysiological and electrochemical sensors on self-contained solid microneedle devices, thereby obviating the need for separate hollow microneedle-based lumens for physiological fluid extraction and an adjoining chamber for which the chemical reaction and/or electrochemical detection are intended to occur. The heterogeneous integration of CMOS- and microneedle-based capabilities into a single package would facilitate a novel means to the construction of self-contained sensor-transducer devices that require substantially less footprint than conventional discrete constituents that comprise current body-worn sensing systems can provide.


BRIEF SUMMARY OF THE INVENTION

The technology described herein relates to methods of integration and packaging of heterogenous semiconductor substrates.


One aspect of the present invention is a skin-adorned physiological or biochemical sensing system. The system comprises a first substrate and a second substrate. The first substrate features an anterior and a posterior surface. The first substrate comprises an array of solid microneedles on the anterior surface designed to penetrate a biological interface to access a physiological fluid or tissue. Each microneedle contains an addressable metal electrode located on the surface of the microneedle which is in electrical communication with a metal surface located on the posterior surface of the first substrate by means of a conductive conduit, to form a sensor component capable of electrical interface with the physiological fluid or tissue. The second substrate has an anterior and a posterior surface. The second substrate comprises integrated circuitry on the anterior surface designed to transduce at least one signal produced by an electrophysiological or electrochemical reaction occurring at the metal electrode, to form a transducer component. The posterior surface of the first substrate is stacked to the anterior surface of the second substrate. The first substrate is bonded to the second substrate to create an electrical interconnect between the first substrate and the second substrate. A sensing system is formed that is capable of interpreting the signal arising from the electrophysiological or electrochemical reaction to ascertain the level of some physiological or biochemical entity.


Yet another aspect of the present invention is a method for the heterogeneous and monolithic integration of a semiconductor-based solid microneedles sensor and a semiconductor-based CMOS circuitry transducer. The method includes bonding a plurality of pads located on the posterior surface of sensor to a plurality of pads on either the anterior or posterior surface of a transducer to facilitate electrical communication between a sensor and the transducer. The sensor comprises a plurality of solid microneedles on the anterior surface of a substrate, each of the plurality of microneedles comprising an addressable sensing electrode. The transducer comprises a potentiostat, an analog front end, an amplifier, a filter, an analog-to-digital converter, microcontroller, and a wireless radio; Each of the plurality of sensing electrodes is accessible on a posterior surface of the substrate by means of a plurality of vertically-oriented conducting channels, wherein at a location on the posterior surface in which each of plurality of vertically-oriented conducting channels exit from the substrate. A plurality of conductive pads are positioned to facilitate bonding to the surface of a second substrate.


Yet another aspect of the present invention is a method for the heterogeneous and monolithic integration of a semiconductor-based solid microneedles sensor and a semiconductor-based CMOS circuitry transducer. The method includes mating a first substrate to a second substrate such that a posterior surface of the first substrate is bonded to an anterior surface of the second substrate. The first substrate contains a transducer and the second substrate containing a sensor. The sensor comprises a plurality of solid microneedles on the anterior surface of a substrate. Each of the plurality of microneedles comprises an addressable sensing electrode. The transducer comprises a potentiostat, an analog front end, an amplifier, a filter, an analog-to-digital converter, microcontroller, and a wireless radio. Each of the plurality of sensing electrodes is accessible on a posterior surface of the substrate by means of a plurality of vertically-oriented conducting channels, wherein at a location on the posterior surface in which each of plurality of vertically-oriented conducting channels exit from the substrate. A plurality of conductive pads are positioned to facilitate bonding to the surface of a second substrate.


Having briefly described the present invention, the above and further objects, features and advantages thereof will be recognized by those skilled in the pertinent art from the following detailed description of the invention when taken in conjunction with the accompanying drawings.





BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWINGS


FIG. 1 is a diagrammatic representation of a die stack with CMOS circuitry on anterior surface of a second die.



FIG. 1A is a diagrammatic representation of a die stack with CMOS circuitry on posterior surface of a second die.



FIG. 1B is a diagrammatic representation of a die stack with CMOS circuitry on anterior surface of a second die and a third die.



FIG. 1C is a diagrammatic representation of a die stack mounted on a printed circuit board containing assorted electrical circuit components, with CMOS circuitry on anterior surface of a second die.



FIG. 1D is a diagrammatic representation of a die stack mounted on a printed circuit board containing assorted electrical circuit components, with CMOS circuitry on anterior surface of a second die.



FIG. 1E is a diagrammatic representation of a die stack mounted on a printed circuit board containing assorted electrical circuit components, with CMOS circuitry on posterior surface of a second die.



FIG. 2 illustrates microneedles on an anterior surface of die and CMOS circuitry on posterior surface of the die.



FIG. 2A illustrates microneedles on an anterior surface of die and CMOS circuitry on posterior surface of the die.



FIG. 2B illustrates microneedles on an anterior surface of die and CMOS circuitry on posterior surface of said die.



FIG. 2C illustrates microneedles on an anterior surface of die and CMOS circuitry on posterior surface of said die.



FIG. 3 illustrates microneedles and CMOS circuitry co-located on an anterior surface of die in spatially distinct regions.



FIG. 3A illustrates microneedles and CMOS circuitry co-located on an anterior surface of die in spatially distinct regions.



FIG. 3B illustrates microneedles and CMOS circuitry co-located on an anterior surface of die in spatially distinct regions.





DETAILED DESCRIPTION OF THE INVENTION

To facilitate increased patient compliance and improve the treatment of acute or chronic disease, body-adorned medical devices such as non-invasive sensor patches as well as minimally-invasive subcutaneously- and intracutaneously-implanted sensors have substantially expanded in use over the past decade. Much of this proliferation has been a result of advancements in electrochemical sensor technology, which enables the quantification of circulating analytes in physiological fluids (blood, interstitial fluid, etc.) in miniaturized and compact platforms. These platforms, which integrate the sensor and transducer constituents into a single device, have been applied to such embodiments as continuous glucose monitoring. Although the current state-of-the-art has resulted in the widespread utilization of body-worn devices in the healthcare domain, the realization of truly low-profile and potentially skin-conformal skin-adorned or skin-adhered medical devices remains elusive as current limitations with electronic device packaging often entails the mounting and interconnect, in a 2-dimensional fashion, of discrete components populating a printed circuit board.


The present invention is a method for the three-dimensional (“3D”) packaging and interconnection of heterogeneous, semiconductor-based systems for body-worn health and wellness devices, such as MEMS-fabricated microneedle arrays and CMOS-based transducers. One aspect of the present invention is a novel method of die attaching via stacking and interconnection of CMOS- and MEMS-based dies as a means to achieve 2.5D or 3D integration. Another aspect of the present invention is a method of fabricating CMOS and MEMS systems on geographically distinct regions of a shared surface of substrate whereby said systems are interconnected to one another by means of conductive traces or through-silicon vias. Another aspect of the present invention is a method of fabricating CMOS and MEMS on opposing surfaces of a substrate whereby interconnect between the two systems is facilitated by through-silicon vias. The ability to perform MEMS-to-CMOS packaging via stacked wire-bonding, reflow soldering of solder balls, or stud-bumping in conjunction with silicon or epoxy interposers enables the construction of vertically-integrated 2.5- or 3-dimensional self-contained sensing systems. Likewise, co-substrate integration of microneedles and CMOS circuitry represents another compelling solution enabled by through-silicon vias (TSVs), flip-chip bonding techniques, or a combination of these capabilities.


The monolithic integration of CMOS-based circuitry and microneedle-based transducers solves several noteworthy challenges confronting those developing technologies in the medical devices and wearable sensors domains. The present invention represents a novel approach to facilitating the synthesis of a heterogeneous, self-contained sensor-transducer system that addresses the shortcomings of the prior art while remaining amenable to highly scalable manufacturing processes.


These prior art shortcomings include the following:


(1) The necessity of interconnect of distinct microneedle-based sensors and CMOS-based transducers, as required for the readout of said microneedles, by means of integration as discrete packaged and mounted/bonded devices populating a printed circuit board: Limitation: A printed circuit board containing discrete microneedle and CMOS systems cannot be easily miniaturized beyond the xy-dimensions associated with said systems as well as the interconnects between the two, thereby placing a technological barrier to the realization of miniaturized skin-worn sensor devices. Moreover, routing electrical connections between two or more such discrete systems on a printed circuit board imposes added constraints of complexity and cost. Mitigation: The utilization of advanced semiconductor processing and packaging techniques facilitates the creation of 2.5- or 3-dimensional, self-contained microneedle-CMOS sensor-transducer systems or heterogeneously integrated microneedle-CMOS architectures sharing a common substrate.


(2) The interconnect of discrete microneedle-based sensors and CMOS-based transducers using conventional PCB traces: Limitation: Interconnect of distinct microneedle and CMOS systems on a printed circuit board is not amenable to maintaining signal fidelity, especially when such signals are analog in nature and reside in the nanoampere/microvolt (or lower) range. Mitigation: As the spatial extent of the interconnect between two electronic systems is directly proportional to noise ingress, the co-location of microneedle and CMOS systems on a shared substrate or the interconnect of said systems by means of solder balls/wire bonds serves to minimize the distance over which said systems interact and hence the noise imparted in the combined system. By reducing interconnect length between the microneedle sensor and CMOS transducer, the chief source of electronic noise and signal degradation is thus minimized.


(3) Inability to scale heterogeneous microneedle- and CMOS-based systems to dimensions enabling unobtrusive, conformal, and flexible skin-adorned medical patches: Limitation: Owing to their disparate manufacturing and packaging requirements, silicon micro-fabricated microneedles and CMOS circuitry have conventionally been packaged as mutually-exclusive, discrete entities populating a printed circuit board. Indeed, heterogeneous integration in a single package or on a single substrate presents difficulty owing to incompatibilities in manufacturing processes and packaging requirements. Mitigation: Employing a monolithic approach to microneedle and CMOS integration, either by means of co-locating the said constituents on the same substrate, or packaging the components as a single stacked entity, heralds the realization of highly miniaturized, self-contained sensing systems capable of direct integration into skin-adorned medical patches characterized by low footprint.


The technology disclosed herein specifies methods to achieve the heterogeneous and monolithic integration of semiconductor-based solid microneedles sensor and the semiconductor-based CMOS circuitry transducer required to interpret readings from the sensor. The sensor preferably contains one or a plurality of solid microneedles on an anterior surface of a substrate, each containing an addressable sensing electrode. The sensor is preferably designed to penetrate a biological interface to access a physiological fluid or tissue. The transducer preferably contains one or a plurality of integrated circuits using complementary metal oxide semiconductor (CMOS) technology. The transducer is preferably designed to control the sensor by applying a specific signal or stimulus to the sensor as well as interpreting the resulting electrical response of the sensor to the signal or stimulus. The transducer preferably includes at least one of the following components: a potentiostat, an analog front end, an amplifier, a filter, an analog-to-digital converter, microcontroller, and a wireless radio. Three approaches may be leveraged to achieve this aim of heterogeneous integration of the sensor and the transducer.


The stacked substrate 10: The sensing electrodes are accessible on the opposing (posterior) surface of the substrate by means of vertically-oriented conducting channels known as through-substrate vias (TSVs), and as described in more detail in Windmiller, et al., U.S. patent application Ser. No. 15/913,709, filed on Mar. 6, 2018, for Methods For Achieving An Isolated Electrical Interface Between An Anterior Surface Of A Microneedle Structure And A Posterior Surface Of A Support Structure is hereby incorporated by reference in its entirety. At a location on a posterior surface in which the TSVs exit from the substrate, conductive pads are found to facilitate bonding to the surface of a second substrate. The conductive pads are preferably located on the posterior surface of the sensor, and are bonded to conductive pads on either the anterior or posterior surface of the transducer to facilitate an electrical communication between the sensor and the transducer. Bonding is achieved by at least one of: stud bumps, solder balls, direct bonding, surface activated bonding, plasma activated bonding, fusion bonding, metal layer bonding, anodic bonding, eutectic bonding, glass frit bonding, insulating layer bonding, adhesive bonding, thermocompression bonding, reactive bonding, transient liquid phase diffusion bonding, physical bonding, and chemical bonding. Optionally, the sensor and the transducer may be wire-bonded to achieve electrical interface between the two systems. Optionally, the transducer (following mating with the sensor) may be mated, in a similar fashion as above, to another CMOS-containing substrate. Optionally, the transducer (following mating with the sensor) may be wire-bonded or stud-bumped and soldered to a printed circuit board to enable electrical communication with discrete electrical or electronic devices such as, but not limited to, batteries, antennas, resistors, capacitors, inductors, diodes, transistors, and discrete semiconductor components.


The Co-Substrate Integration: The sensing electrodes are accessible on the opposing (posterior) surface of the substrate by means of vertically-oriented conducting channels known as through-substrate vias (TSVs). At a location on the posterior surface in which the TSVs exit from the substrate, conductive traces are found to route signals generated by the sensor to the transducer to facilitate an electrical communication between the sensor located on the anterior surface of substrate and the transducer located on the posterior surface of substrate. Optionally, the substrate (hereinafter referred to as the first substrate) may be mated to another CMOS-containing substrate (second substrate) such that the posterior surface of the first substrate (containing the transducer) is bonded to the anterior surface of the second substrate by means of at least one of: stud bumps, solder balls, direct bonding, surface activated bonding, plasma activated bonding, fusion bonding, metal layer bonding, anodic bonding, eutectic bonding, glass frit bonding, insulating layer bonding, adhesive bonding, thermocompression bonding, reactive bonding, transient liquid phase diffusion bonding, physical bonding, and chemical bonding. Optionally, the first substrate or the second substrate (if present) may be wire-bonded or stud-bumped and soldered to a printed circuit board to enable electrical communication with discrete electrical or electronic devices such as, but not limited to, batteries, antennas, resistors, capacitors, inductors, diodes, transistors, and discrete semiconductor components.


The Co-Planar Integration: The sensing electrodes are accessible on the same (anterior) surface of the substrate by means of horizontally-oriented conducting traces. The conductive traces route electrical signals generated by sensor to the transducer to facilitate an electrical communication between the sensor and the transducer, both co-located on spatially distinct regions on the anterior surface of the substrate. Optionally, the substrate (hereinafter referred to as the first substrate) may be mated to another CMOS-containing silicon die (second substrate) such that the posterior surface of the first substrate is bonded to the anterior surface of the second substrate by means of at least one of: stud bumps, solder balls, direct bonding, surface activated bonding, plasma activated bonding, fusion bonding, metal layer bonding, anodic bonding, eutectic bonding, glass frit bonding, insulating layer bonding, adhesive bonding, thermocompression bonding, reactive bonding, transient liquid phase diffusion bonding, physical bonding, and chemical bonding. Optionally, the first substrate or the second substrate may be wire-bonded or stud-bumped and soldered to a printed circuit board to enable electrical communication with discrete electrical or electronic devices such as, but not limited to, batteries, antennas, resistors, capacitors, inductors, diodes, transistors, and discrete semiconductor components.


Under each of the above scenarios, the substrate may comprise a semiconductor wafer or die selected from one of the Group IV elements (i.e. Silicon, Germanium), the Group VI elements (i.e. Selenium, Tellurium), composites comprising II-VI elements (i.e. Cadmium Sulfide, Zinc Oxide), and composites comprising III-V elements (i.e. Gallium Arsenide, Indium Phosphide); the TSV may comprise the doped or intrinsically conducting species of the above materials as well as a metal.


The microneedle sensor 5 breaches a biological interface to access a physiological fluid or tissue. The microneedle sensor 5 contains one or a plurality of solid microneedles on the anterior surface of a silicon substrate 10, each of the microneedle constituents contain an addressable sensing electrode in physical contact with the physiological fluid or tissue. In addition, the sensing electrode(s) are in direct electrical communication either with another region on the anterior surface of the silicon substrate (by means of metallic traces/conduits) or on the posterior surface of the substrate (by means of through-silicon vias 1). The microneedle sensor 5 is designed to stimulate, sustain, and provide a means to read out some electrophysiological or electrochemical signal or reaction at the electrode surface.


The CMOS transducer 30 converts some variations in electrophysiological or electrochemical quantities arising at the interface of the microneedle sensor 5 and the biological interface into an electrical signal or vice versa. The CMOS transducer 30 transduces the signal(s) produced by the microneedle sensor 5 to information capable of being interpreted to ascertain the level of some physiological or biochemical entity. The CMOS transducer 30 contains complementary metal oxide semiconductor circuitry, patterned on a silicon substrate, to implement at least one of the following functionalities: a potentiostat, an analog front end, an amplifier, a filter, an analog-to-digital converter, microcontroller, and a wireless radio. Optionally the CMOS transducer 30 can control the microneedle sensor 5 by applying a certain potential, current, or frequency-modulated signal while simultaneously quantifying the electrical response of the microneedle sensor 5. Optionally the CMOS transducer 30 can perform processing on the signal to mitigate noise and can feature a wireless capability to relay said raw or processed signal to another device. Optionally the CMOS transducer 30 can interface with a display to present the user with sensor readings.


The semiconductor substrates 10 provide a mechanical support for the implementation of sensor and transducer constituents. The semiconductor substrates 10 are comprised of a semiconductor wafer or die selected from one of the Group IV elements (i.e. Silicon, Germanium), the Group VI elements (i.e. Selenium, Tellurium), composites comprising II-VI elements (i.e. Cadmium Sulfide, Zinc Oxide), and composites comprising III-V elements (i.e. Gallium Arsenide, Indium Phosphide).


Through-substrate via 1 facilitate an electrical interconnect between anterior and posterior surfaces of a semiconductor substrate 10. The through-substrate vias 1 are comprised of a doped or intrinsically conducting species of the Group IV, Group VI semiconductor elements or binary semiconductor compounds comprising the II-VI and III-V elements. Optionally the through-substrate vias 1 may be comprised of a metal or metal alloy. In the case that the substrate 10 is comprised of silicon, this is also referred to as a through-silicon via 1.


Stud bumps/solder balls/epoxy 23 facilitate an electrical interconnect between two disparate substrates (silicon 10, PCB 35, or combination of the two).


Bond wire 50 facilitates an electrical interconnect between two disparate substrates (silicon 10, PCB 35, or combination of the two). The bond wire 50 is preferably comprised of a metal or metal alloy.



FIGS. 1-1E illustrate diagrammatic representations of various die-stacking devices 20 that achieve heterogeneous integration of silicon-fabricated solid microneedle sensors and CMOS circuitry. FIG. 1 illustrates a skin-adorned physiological or biochemical sensing device 20 with a first die stack 10 with a CMOS circuitry 30 on an anterior surface of a second die 15. Each of the microneedles 5 is on a posterior pad 11 with stud bumps/sold balls/conductive epoxy 23 between the posterior pads 11 and anterior pads 17. FIG. 1A illustrates a first die stack 10 with CMOS circuitry 30 on posterior surface of second die 15, enabled by the presence of through-substrate vias 1. FIG. 1B illustrates a first die stack 10 with CMOS circuitry 30 on an anterior surface of a second die 15 and a third die 20, enabled by the presence of through-substrate vias 1 on the second die 15. FIG. 1C illustrates a first die stack 10, mounted on a printed circuit board (“PCB”) 35 containing assorted electrical circuit components, with CMOS circuitry 30 on an anterior surface of a second die 15, enabled by the presence of through-substrate vias 1 on the second die 15. FIG. 1D illustrates a first die stack 10, mounted on a PCB 35 containing assorted electrical circuit components, with CMOS circuitry 30 on anterior surface of a second die 15, enabled by the presence of wire bonds 50 on the second die 15. FIG. 1E illustrates a die stack, mounted on a PCB 35 which comprises electrical circuit components 37 such as a potentiostat, an analog front end, an amplifier, a filter, an analog-to-digital converter, microcontroller, and a wireless radio, with CMOS circuitry 30 on a posterior surface of the second die 15, enabled by the presence of through-substrate vias 1 on both the second die 15 and PCB 35, and through anterior conductive pads 36 on the PCB 35, which are connected to posterior conductive pads 16 of the second die 15. A TSV 40 through the PCB 35 enables the connection to the electrical components 37 located on the posterior surface of the PCB 35.



FIGS. 2-2C illustrate diagrammatic representations of various co-substrate devices 20 that achieve heterogeneous integration of silicon-fabricated solid microneedle sensors and CMOS circuitry. As shown in FIGS. 2 and 2A, microneedles 5 are positioned on an anterior surface of die 10 with CMOS circuitry 30 on a posterior surface of the die 10, and an interconnect between the microneedles 5 and the CMOS circuitry 30 is enabled by the presence of through-substrate vias 1 positioned colinearly with the microneedles 5 and a conductive trace 45. A bonding pad 51 is positioned on the CMOS circuitry 30. Posterior pads 11 are positioned below the microneedles 5. As shown in FIG. 2B, microneedles 5 are positioned on an anterior surface of a die 10 with CMOS circuitry 30 on a posterior surface of the die 10, and an interconnect is enabled by the presence of through-substrate vias 1 positioned in a spatially distinct region from the microneedles 5. As shown in FIG. 2C, the microneedles 5 are positioned on an anterior surface of a die 10 with CMOS circuitry 30 on a posterior surface of the die 10, and an interconnect is enabled by the presence of through-substrate vias 1 positioned colinearly with the microneedles 5, and the die 10 is mounted on a PCB 35 which comprises electrical circuit components 37 such as a potentiostat, an analog front end, an amplifier, a filter, an analog-to-digital converter, microcontroller, and a wireless radio, with an electrical interconnect achieved between the die 10 and the PCB 35 by means of stud bumps 23, solder balls 23, and/or conductive epoxy 23, and with an anterior conductive pad 36. A TSV 40 connects traces 45 on the anterior surface and posterior surface of the PCB 35.



FIGS. 3-3B illustrate diagrammatic representations of various co-planar devices 20 that achieve heterogeneous integration of silicon-fabricated solid microneedle sensors and CMOS circuitry. As shown in FIGS. 3 and 3A, microneedles 5 and CMOS circuitry 30 are co-located on an anterior surface of a die 10 in spatially distinct regions, and interconnects between the microneedles 5 and the CMOS circuitry 30 are enabled by the presence of conductive traces 45 positioned co-planarly with the CMOS circuitry 30. Anterior bonding pads 51 are on an anterior surface of the die 10. A TSV 1 connects the CMOS circuitry 30 to the anterior bonding pad 51. As shown in FIG. 3B, microneedles 5 and CMOS circuitry 30 are co-located on an anterior surface of a die 10 in spatially distinct regions, and interconnects between the microneedles 5 and the CMOS circuitry 30 are enabled by the presence of conductive traces 45 positioned co-planarly with the CMOS circuitry 30. The die 10 is mounted on a PCB 35 which comprises electrical circuit components 37 such as a potentiostat, an analog front end, an amplifier, a filter, an analog-to-digital converter, microcontroller, and a wireless radio. An electrical interconnect is achieved between the die 10 and the PCB 35 by means of through-substrate vias 1 in conjunction with stud bumps 23, solder balls 23, and/or conductive epoxy 23, and with an anterior conductive pad 36. A TSV 40 connects traces 45 on the anterior surface and posterior surface of the PCB 35.


One embodiment is a skin-adorned physiological or biochemical sensing device 20. The device 20 comprises a first substrate 10 and a second substrate 15. The first substrate 10 comprises an anterior surface and a posterior surface. The first substrate 10 comprises an array of solid microneedles 5 on the anterior surface designed to penetrate a biological interface to access a physiological fluid or tissue. Each microneedle 5 contains an addressable metal electrode located on the surface of the microneedle 5 which is in electrical communication with a metal surface located on the posterior surface of the first substrate 10 by means of a conductive conduit 1, to form a microneedle sensor component 5 capable of electrical interface with the physiological fluid or tissue. The conductive conduit 1 preferably comprises at least one of a through-substrate via 1. The through-substrate via 1 is preferably comprised of a doped or intrinsically conducting semiconductor; said semiconductor includes at least one of silicon, germanium, silicon germanium, gallium arsenide, indium phosphide, gallium nitride, zinc oxide, and cadmium selenide. The second substrate 15 has an anterior and a posterior surface. The second substrate 15 comprises integrated circuitry 30 on the anterior surface designed to transduce at least one signal produced by an electrophysiological or electrochemical reaction occurring at the metal electrode, to form a transducer component. The posterior surface of the first substrate 10 is stacked to the anterior surface of the second substrate 15. The first substrate 10 is bonded to the second substrate 15 to create an electrical interconnect between the first substrate 10 and the second substrate 15. A sensing device 20 is formed that is capable of interpreting the signal arising from the electrophysiological or electrochemical reaction to ascertain the level of some physiological or biochemical entity.


The first substrate is preferably a semiconductor that includes at least one of silicon, germanium, silicon germanium, gallium arsenide, indium phosphide, gallium nitride, zinc oxide, and cadmium selenide.


The electrical interface preferably includes at least one of applying an electrical stimulus to said physiological fluid or tissue and detecting an electrical signal arising within said physiological fluid or tissue. The electrical stimulus includes at least one of a DC voltage, DC current, AC voltage, AC current, frequency-modulated signal, amplitude-modulated signal, or phase-modulated signal. The electrical signal includes at least one of a DC voltage, DC current, AC voltage, AC current, frequency-modulated signal, amplitude-modulated signal, or phase-modulated signal.


The integrated circuitry 30 preferably comprises at least one of a potentiostat, an analog front end, an amplifier, a filter, an analog-to-digital converter, microcontroller, and a wireless radio.


The bonding means is at least one of stud bumps, solder balls, direct bonding, surface activated bonding, plasma activated bonding, fusion bonding, metal layer bonding, anodic bonding, eutectic bonding, glass frit bonding, insulating layer bonding, adhesive bonding, thermocompression bonding, reactive bonding, transient liquid phase diffusion bonding, physical bonding, and chemical bonding.


The second substrate 15 is further attached to a PCB 35 by means of at least one of: wire bonds 50, stud bumps 23, and solder balls 23.


The PCB 35 preferably comprises discrete electrical or electronic devices such as, but not limited to, batteries, antennas, resistors, capacitors, inductors, diodes, transistors, and discrete semiconductor components.


McCanna et al., U.S. patent application Ser. No. 14/843,926, filed on Sep. 2, 2015, for a Miniaturized Sub-Nanoampere Sensitivity Low-Noise Potentiostat System is hereby incorporated by reference in its entirety.


Windmiller et al., U.S. patent application Ser. No. 14/955,850, filed on Dec. 1, 2015, for a Method And Apparatus For Determining Body Fluid Loss is hereby incorporated by reference in its entirety.


Windmiller, U.S. patent application Ser. No. 15/177,289, filed on Jun. 8, 2016, for a Methods And Apparatus For Interfacing A Microneedle-Based Electrochemical Biosensor With An External Wireless Readout Device is hereby incorporated by reference in its entirety.


Wang et al., U.S. Patent Publication Number 20140336487 for a Microneedle Arrays For Biosensing And Drug Delivery is hereby incorporated by reference in its entirety.


Windmiller, U.S. patent application Ser. No. 15/590,105 for a Tissue-Penetrating Electrochemical Sensor Featuring A Co Electrodeposited Thin Film Comprised Of A Polymer And Bio-Recognition Element is hereby incorporated by reference in its entirety.


Windmiller, et al., U.S. patent application Ser. No. 15/913,709, filed on Mar. 6, 2018, for Methods For Achieving An Isolated Electrical Interface Between An Anterior Surface Of A Microneedle Structure And A Posterior Surface Of A Support Structure is hereby incorporated by reference in its entirety.


PCT Application Number PCT/US17/55314 for an Electro Deposited Conducting Polymers For The Realization Of Solid-State Reference Electrodes For Use In Intracutaneous And Subcutaneous Analyte-selective Sensors is hereby incorporated by reference in its entirety.


From the foregoing it is believed that those skilled in the pertinent art will recognize the meritorious advancement of this invention and will readily understand that while the present invention has been described in association with a preferred embodiment thereof, and other embodiments illustrated in the accompanying drawings, numerous changes modification and substitutions of equivalents may be made therein without departing from the spirit and scope of this invention which is intended to be unlimited by the foregoing except as may appear in the following appended claim. Therefore, the embodiments of the invention in which an exclusive property or privilege is claimed are defined in the following appended claims.

Claims
  • 1. A skin-adorned sensing device, comprising: a first substrate comprising: an anterior surface comprising an array of microneedles configured to sense an electrophysiological or electrochemical reaction within physiological fluid or tissue, wherein each microneedle of the array of microneedles comprises an addressable electrode located on a surface of the microneedle;a posterior surface comprising a first conductive pad; anda first conductive conduit extending through the first substrate and configured to provide electrical communication between the addressable electrode of a first microneedle of the array of microneedles and the first conductive pad;a second substrate comprising: a second conductive pad in electrical communication with the first conductive pad of the first substrate;a third conductive pad positioned posterior to the second conductive pad; anda second conductive conduit extending through the second substrate and configured to provide electrical communication between the second conductive pad and the third conductive pad,wherein a posterior surface of the second substrate comprises a CMOS circuitry transducer; anda printed circuit board comprising an anterior conductive pad, the anterior conductive pad in electrical communication with the third conductive pad of the second substrate.
  • 2. The device of claim 1, wherein one or both of the first conductive conduit and the second conductive conduit comprises a through-substrate via.
  • 3. The device of claim 1, wherein the CMOS circuitry transducer comprises one or more of: a potentiostat, a galvanostat, an analog front end, an amplifier, a filter, an analog-to-digital converter, a microcontroller, and a wireless radio.
  • 4. The device of claim 1, wherein the first substrate and the second substrate are bonded by solder.
  • 5. The device of claim 1, wherein the first substrate and the second substrate are bonded by solder and epoxy.
  • 6. The device of claim 1, wherein the printed circuit board further comprises: one or more electrical circuit components on a posterior surface of the printed circuit board; anda through substrate via between the anterior conductive pad of the printed circuit board and the one or more electrical circuit components.
  • 7. The device of claim 6, wherein the one or more electrical circuit components comprise one or more of a potentiostat, an analog front end, an amplifier, a filter, an analog-to-digital converter, microcontroller, a wireless radio, a battery, and an antenna.
  • 8. The device of claim 1, wherein the second substrate is bonded to the printed circuit board by stud bumps.
  • 9. The device of claim 1, wherein the array of microneedles is configured to penetrate a user's skin to access the physiological fluid or tissue.
  • 10. The device of claim 1, wherein the device is configured to interpret a signal produced by the electrophysiological or electrochemical reaction occurring at the array of microneedles to determine a level of a physiological or biochemical entity.
  • 11. A skin-adorned sensing device comprising: a die stack mounted on a printed circuit board, the die stack comprising: a first substrate comprising: an array of microneedles configured to sense an electrophysiological or electrochemical reaction within physiological fluid or tissue; anda first conductive conduit in electrical communication with a first microneedle of the array of microneedles and extending through the first substrate; anda second substrate comprising: a second conductive conduit extending through the second substrate and longitudinally aligned with the first conductive conduit,wherein the first conductive conduit and the second conductive conduit are configured to provide electrical communication between the first microneedle of the array of microneedles and the printed circuit board,wherein a posterior surface of the second substrate comprises a CMOS circuitry transducer; andwherein the device is configured to interpret a signal produced by an electrophysiological or electrochemical reaction occurring at the first microneedle of the array of microneedles to determine a level of a physiological or biochemical entity.
  • 12. The device of claim 11, wherein one or both of the first conductive conduit and the second conductive conduit comprise a through-substrate via.
  • 13. The device of claim 12, wherein the through-substrate via comprises one or more of silicon, germanium, silicon germanium, gallium arsenide, indium phosphide, gallium nitride, zinc oxide, and cadmium selenide.
  • 14. The device according to claim 11, wherein the printed circuit board comprises electrical circuit components configured to perform the interpreting and the determining, the electrical circuit components comprising one or more of a potentiostat, an analog front end, an amplifier, a filter, an analog-to-digital converter, microcontroller, and a wireless radio.
  • 15. The device of claim 14, wherein the die stack is mounted to an anterior surface of the printed circuit board, and wherein the electrical circuit components are on a posterior surface of the printed circuit board.
  • 16. The device of claim 15, wherein an electrical connection between the die stack and the printed circuit board is formed by an anterior conductive pad positioned on the anterior surface of the printed circuit board.
  • 17. The device of claim 14, wherein the printed circuit board comprises a through-substrate via that provides electrical communication between the die stack and the electrical circuit components.
  • 18. The device of claim 11, wherein the device is further configured to apply an electrical stimulus to the physiological fluid or tissue to sustain the electrophysiological or electrochemical reaction.
  • 19. A method for quantifying a physiological or biochemical entity in a physiological fluid or tissue, the method comprising: providing a die stack mounted on a printed circuit board, the die stack comprising: a first substrate comprising: an anterior surface comprising an array of microneedles configured to sense an electrophysiological or electrochemical reaction within physiological fluid or tissue; anda first conductive conduit in electrical communication with a first microneedle of the array of microneedles and extending through the first substrate; anda second substrate comprising: a second conductive conduit extending through the second substrate and longitudinally aligned with the first conductive conduit,wherein the first conductive conduit and the second conductive conduit are configured to provide electrical communication between the first microneedle of the array of microneedles and the printed circuit board, andwherein a posterior surface of the second substrate comprises a CMOS circuitry transducer;penetrating a biological interface with the array of microneedles;routing a signal produced by an electrophysiological or electrochemical reaction within the physiological fluid or tissue from a first microneedle of the array of microneedles to a printed circuit board via the first conductive conduit, the CMOS circuitry transducer, and the second conductive conduit; andinterpreting the signal with the printed circuit board to determine a level of the physiological or biochemical entity.
  • 20. The method of claim 19, further comprising applying an electrical stimulus to the physiological fluid or tissue with the first microneedle of the array of microneedles.
  • 21. The method of claim 20, further comprising sustaining the electrophysiological or electrochemical reaction within the physiological fluid or tissue by continuously applying the electrical stimulus.
CROSS REFERENCES TO RELATED APPLICATIONS

The Present Application is a continuation application of U.S. patent application Ser. No. 15/961,793, filed on Apr. 24, 2018, which claims priority to U.S. Provisional Patent Application No. 62/492,142, filed on Apr. 29, 2017, each of which is hereby incorporated by reference in its entirety.

US Referenced Citations (398)
Number Name Date Kind
4305401 Reissmueller et al. Dec 1981 A
4323996 Ganter Apr 1982 A
4407295 Steuer et al. Oct 1983 A
4450842 Zick et al. May 1984 A
4908117 Kinlen et al. Mar 1990 A
4969468 Byers et al. Nov 1990 A
5035711 Aoki et al. Jul 1991 A
5131390 Sakaguchi et al. Jul 1992 A
5279543 Glikfeld et al. Jan 1994 A
5286364 Yacynych et al. Feb 1994 A
5540828 Yacynych Jul 1996 A
5730714 Guy et al. Mar 1998 A
5766132 Yasukawa et al. Jun 1998 A
5832410 Lin et al. Nov 1998 A
5869078 Baudino Feb 1999 A
5953306 Yi Sep 1999 A
6036055 Mogadam et al. Mar 2000 A
6091975 Daddona et al. Jul 2000 A
6132449 Lum et al. Oct 2000 A
6132499 Wong et al. Oct 2000 A
6132755 Eicher et al. Oct 2000 A
6139718 Kurnik et al. Oct 2000 A
6269053 Kawata et al. Jul 2001 B1
6284126 Kurnik et al. Sep 2001 B1
6364890 Lum et al. Apr 2002 B1
6413396 Yang et al. Jul 2002 B1
6465091 Ou-yang Oct 2002 B1
6471903 Sherman et al. Oct 2002 B2
6527762 Santini, Jr. et al. Mar 2003 B1
6551849 Kenney Apr 2003 B1
6587705 Kim et al. Jul 2003 B1
6599408 Chan et al. Jul 2003 B1
6603987 Whitson Aug 2003 B2
6611707 Prausnitz et al. Aug 2003 B1
6793789 Choi et al. Sep 2004 B2
6801041 Karinka et al. Oct 2004 B2
6814845 Wilson et al. Nov 2004 B2
6862466 Ackerman Mar 2005 B2
6908453 Fleming et al. Jun 2005 B2
7081195 Simpson et al. Jul 2006 B2
7097776 Govinda Raju Aug 2006 B2
7132054 Kravitz et al. Nov 2006 B1
7262068 Roy et al. Aug 2007 B2
7343188 Sohrab Mar 2008 B2
7344499 Prausnitz et al. Mar 2008 B1
7366556 Brister et al. Apr 2008 B2
7415299 Zimmermann et al. Aug 2008 B2
7429333 Chiou et al. Sep 2008 B2
7456112 Lee Nov 2008 B2
7471972 Rhodes et al. Dec 2008 B2
7473244 Frazier et al. Jan 2009 B2
7493232 Surina Feb 2009 B1
7534330 Yu et al. May 2009 B2
7583990 Goode, Jr. Sep 2009 B2
7599726 Goode, Jr. Oct 2009 B2
7613491 Boock Nov 2009 B2
7645263 Angel et al. Jan 2010 B2
7715893 Kamath et al. May 2010 B2
7768408 Reggiardo et al. Aug 2010 B2
7778680 Goode, Jr. Aug 2010 B2
7797028 Goode, Jr. Sep 2010 B2
7811231 Jin et al. Oct 2010 B2
7837654 Shumate et al. Nov 2010 B2
7885697 Brister et al. Feb 2011 B2
7905833 Brister et al. Mar 2011 B2
7917186 Kamath et al. Mar 2011 B2
7949382 Jina May 2011 B2
7959569 Goode et al. Jun 2011 B2
8005526 Martin et al. Aug 2011 B2
8010174 Goode, Jr. Aug 2011 B2
8022292 Arianpour et al. Sep 2011 B2
8064977 Boock et al. Nov 2011 B2
8088321 Ferguson et al. Jan 2012 B2
8094009 Allen et al. Jan 2012 B2
8108023 Mir et al. Jan 2012 B2
8110079 Gooding et al. Feb 2012 B2
8125331 Allen et al. Feb 2012 B2
8130095 Allen et al. Mar 2012 B2
8160665 Mischler et al. Apr 2012 B2
8160671 Kamath et al. Apr 2012 B2
8160834 Liang et al. Apr 2012 B2
8162901 Gonnelli et al. Apr 2012 B2
RE43399 Simpson et al. May 2012 E
8216138 McGarraugh Jul 2012 B1
8236368 Jung et al. Aug 2012 B2
8249684 Kamath et al. Aug 2012 B2
8257324 Prausnitz et al. Sep 2012 B2
8280475 Brister et al. Oct 2012 B2
8280476 Jina Oct 2012 B2
8284046 Allen et al. Oct 2012 B2
8287453 Li et al. Oct 2012 B2
8308960 Kälvesten et al. Nov 2012 B2
8346335 Harper et al. Jan 2013 B2
8376945 Hayter et al. Feb 2013 B2
8386004 Kamath et al. Feb 2013 B2
8423114 Simpson et al. Apr 2013 B2
8428678 Kamath et al. Apr 2013 B2
8452369 Huys May 2013 B2
8463350 Kamath et al. Jun 2013 B2
8483793 Simpson et al. Jul 2013 B2
8506529 Yang Aug 2013 B1
8548553 Kamath et al. Oct 2013 B2
8565848 Brister et al. Oct 2013 B2
8574165 Marsh Nov 2013 B2
8617069 Bernstein et al. Dec 2013 B2
RE44695 Simpson et al. Jan 2014 E
8626257 Li et al. Jan 2014 B2
8637351 Kälvesten et al. Jan 2014 B2
8660628 Wang et al. Feb 2014 B2
8708966 Allen et al. Apr 2014 B2
8798799 Deo et al. Aug 2014 B2
8815070 Wang et al. Aug 2014 B2
8870763 Yang et al. Oct 2014 B2
8882665 Yang et al. Nov 2014 B2
9008743 Hayter et al. Apr 2015 B2
9008745 Pushpala et al. Apr 2015 B2
9055901 Brister et al. Jun 2015 B2
9125625 Wang et al. Sep 2015 B2
9182368 Pushpala et al. Nov 2015 B2
9234872 Homyk et al. Jan 2016 B2
9248273 Guvanasen et al. Feb 2016 B2
9332934 Hayter et al. May 2016 B2
9336423 Goodnow et al. May 2016 B2
9357951 Simpson et al. Jun 2016 B2
9386954 Saini et al. Jul 2016 B2
9387000 Corrie et al. Jul 2016 B2
9414778 Mao et al. Aug 2016 B2
9420965 Brauker et al. Aug 2016 B2
9532741 Brauker et al. Jan 2017 B2
9551698 Huys et al. Jan 2017 B2
9662056 Budiman et al. May 2017 B2
9737247 Wang et al. Aug 2017 B2
9743870 Wang et al. Aug 2017 B2
9743871 Simpson et al. Aug 2017 B2
9757061 Shults et al. Sep 2017 B2
9770211 Hayter et al. Sep 2017 B2
9804114 Rhodes et al. Oct 2017 B2
9933387 McCanna et al. Apr 2018 B1
9958409 Gerber et al. May 2018 B2
10022076 Hoss et al. Jul 2018 B2
10039480 Brauker et al. Aug 2018 B2
10046114 Biederman et al. Aug 2018 B1
10052055 Li et al. Aug 2018 B2
10092207 Windmiller Oct 2018 B1
10136846 Wang et al. Nov 2018 B2
10173042 Pushpala et al. Jan 2019 B2
10182748 Catt et al. Jan 2019 B2
10188333 Kamath et al. Jan 2019 B2
10228341 Katsuki et al. Mar 2019 B2
10299712 Brister et al. May 2019 B2
10327678 Gottlieb et al. Jun 2019 B2
10492708 Windmiller Dec 2019 B1
D875254 Cooke et al. Feb 2020 S
10549080 Pushpala et al. Feb 2020 B2
10610103 Brister et al. Apr 2020 B2
10709332 Brister et al. Jul 2020 B2
10743800 Larvenz et al. Aug 2020 B2
10820860 Pushpala et al. Nov 2020 B2
10881334 Facchinetti et al. Jan 2021 B2
10932700 Simpson et al. Mar 2021 B2
10983083 Harding et al. Apr 2021 B2
11020026 Boock et al. Jun 2021 B2
11035872 Boutelle et al. Jun 2021 B2
11045142 Windmiller et al. Jun 2021 B1
11051724 Pace et al. Jul 2021 B2
11123532 Pushpala et al. Sep 2021 B2
11179068 Pace et al. Nov 2021 B2
11197985 Pushpala et al. Dec 2021 B2
11272866 Pushpala et al. Mar 2022 B2
11272885 Pushpala et al. Mar 2022 B2
11291390 Pushpala et al. Apr 2022 B2
11331022 Halac et al. May 2022 B2
11359300 Beer et al. Jun 2022 B1
11406818 Windmiller Aug 2022 B2
11478194 Windmiller et al. Oct 2022 B2
11596332 Shults et al. Mar 2023 B2
11654270 Mansfield, III et al. May 2023 B2
D988160 Morelock Jun 2023 S
11672965 Mansfield, III et al. Jun 2023 B2
20020004640 Conn et al. Jan 2002 A1
20020020688 Sherman et al. Feb 2002 A1
20020055704 Scott et al. May 2002 A1
20020072784 Norman, Jr. et al. Jun 2002 A1
20020105080 Speakman Aug 2002 A1
20020187556 Shartle et al. Dec 2002 A1
20030088166 Say et al. May 2003 A1
20030095582 Ackley May 2003 A1
20030100040 Bonnecaze et al. May 2003 A1
20030104119 Wilson et al. Jun 2003 A1
20030135158 Gonnelli Jul 2003 A1
20030208167 Prausnitz et al. Nov 2003 A1
20030225360 Eppstein et al. Dec 2003 A1
20030235817 Bartkowiak et al. Dec 2003 A1
20040065158 Schrepfer et al. Apr 2004 A1
20040082875 Donoghue et al. Apr 2004 A1
20040220625 Silvestri et al. Nov 2004 A1
20050036020 Li et al. Feb 2005 A1
20050137536 Gonnelli Jun 2005 A1
20050209565 Yuzhakov et al. Sep 2005 A1
20050267440 Herman et al. Dec 2005 A1
20050272989 Shah et al. Dec 2005 A1
20060015061 Kuo et al. Jan 2006 A1
20060016700 Brister et al. Jan 2006 A1
20060173259 Flaherty et al. Aug 2006 A1
20060264716 Zander Nov 2006 A1
20060281121 Unger et al. Dec 2006 A1
20070078445 Malloy Apr 2007 A1
20070169533 Shah et al. Jul 2007 A1
20070170054 Wilsey Jul 2007 A2
20070213044 Steingart et al. Sep 2007 A1
20070282246 Henley Dec 2007 A1
20080009800 Nickel Jan 2008 A1
20080009801 Nickel Jan 2008 A1
20080027369 Carter et al. Jan 2008 A1
20080033269 Zhang Feb 2008 A1
20080097280 Martin et al. Apr 2008 A1
20080097352 Beck et al. Apr 2008 A1
20080119707 Stafford May 2008 A1
20080154107 Jina Jun 2008 A1
20080156661 Cooper et al. Jul 2008 A1
20080213461 Gill et al. Sep 2008 A1
20080221408 Hoarau et al. Sep 2008 A1
20080234562 Jina Sep 2008 A1
20080255434 Hayter et al. Oct 2008 A1
20080275327 Faarbaek et al. Nov 2008 A1
20090057148 Wieder et al. Mar 2009 A1
20090066348 Shin et al. Mar 2009 A1
20090069651 Zimmermann et al. Mar 2009 A1
20090069697 Frazier et al. Mar 2009 A1
20090084678 Joshi et al. Apr 2009 A1
20090088652 Tremblay Apr 2009 A1
20090090623 Chuang et al. Apr 2009 A1
20090099427 Jina et al. Apr 2009 A1
20090101498 Papadimitrakopoulos et al. Apr 2009 A1
20090131778 Jina et al. May 2009 A1
20090143761 Cantor et al. Jun 2009 A1
20090152598 Baek et al. Jun 2009 A1
20090191616 Lu et al. Jul 2009 A1
20090198118 Hayter et al. Aug 2009 A1
20090218239 Gooding et al. Sep 2009 A1
20090259118 Feldman et al. Oct 2009 A1
20090294306 Feldman et al. Dec 2009 A1
20100006451 Gordon et al. Jan 2010 A1
20100021637 Revol et al. Jan 2010 A1
20100025238 Gottlieb et al. Feb 2010 A1
20100030045 Gottlieb et al. Feb 2010 A1
20100049021 Jina et al. Feb 2010 A1
20100052892 Allen et al. Mar 2010 A1
20100052897 Allen et al. Mar 2010 A1
20100052898 Allen et al. Mar 2010 A1
20100052915 Allen et al. Mar 2010 A1
20100056873 Allen et al. Mar 2010 A1
20100137779 Seitz Jun 2010 A1
20100200538 Petisce et al. Aug 2010 A1
20100279377 Shah et al. Nov 2010 A1
20100286803 Tillotson et al. Nov 2010 A1
20110027127 Simpson et al. Feb 2011 A1
20110077490 Simpson et al. Mar 2011 A1
20110105871 Zimmermann et al. May 2011 A1
20110140703 Chiao et al. Jun 2011 A1
20110224515 Mir et al. Sep 2011 A1
20110230736 Tepper et al. Sep 2011 A1
20110237925 Yue et al. Sep 2011 A1
20110247934 Wang et al. Oct 2011 A1
20110275918 Yamashita et al. Nov 2011 A1
20110306853 Black et al. Dec 2011 A1
20110319787 Lamoise et al. Dec 2011 A1
20120018302 Shiraki et al. Jan 2012 A1
20120037515 Solanki Feb 2012 A1
20120067734 Wang et al. Mar 2012 A1
20120078071 Bohm et al. Mar 2012 A1
20120123232 Najarian et al. May 2012 A1
20120172692 Tamada et al. Jul 2012 A1
20120209244 Gray Aug 2012 A1
20120277629 Bernstein et al. Nov 2012 A1
20120323097 Chowdhury Dec 2012 A9
20130053660 Shieh Feb 2013 A1
20130065257 Wang et al. Mar 2013 A1
20130135158 Faraone et al. May 2013 A1
20130144131 Wang et al. Jun 2013 A1
20130158376 Hayter et al. Jun 2013 A1
20130225956 Huang et al. Aug 2013 A1
20130281808 Shieh Oct 2013 A1
20130338746 Guvanasen et al. Dec 2013 A1
20130345597 Hagino et al. Dec 2013 A1
20140135679 Mann et al. May 2014 A1
20140259652 Pushpala et al. Sep 2014 A1
20140275897 Pushpala et al. Sep 2014 A1
20140275899 Gottlieb et al. Sep 2014 A1
20140275907 Feldman et al. Sep 2014 A1
20140303471 Rajaraman Oct 2014 A1
20140336487 Wang et al. Nov 2014 A1
20140378804 Kalvesten et al. Dec 2014 A1
20150073238 Matsumoto et al. Mar 2015 A1
20150126834 Wang et al. May 2015 A1
20150208970 Huang Jul 2015 A1
20150243851 Lee et al. Aug 2015 A1
20150276758 Addisu Oct 2015 A1
20150313527 Renlund Nov 2015 A1
20160029937 Sia et al. Feb 2016 A1
20160058342 Maiz-Aguinaga Mar 2016 A1
20160095541 Wang et al. Apr 2016 A1
20160095547 Wang et al. Apr 2016 A1
20160139069 Wang May 2016 A1
20160157764 Di Palma Jun 2016 A1
20160158514 Stoeber et al. Jun 2016 A1
20160166184 Teng et al. Jun 2016 A1
20160258945 Malima et al. Sep 2016 A1
20160270704 Deturk Sep 2016 A1
20160296149 Polsky et al. Oct 2016 A1
20160302687 Lee et al. Oct 2016 A1
20160370377 Ahmad Dec 2016 A1
20170003766 Budiman Jan 2017 A1
20170007813 Negi et al. Jan 2017 A1
20170035331 Parajape et al. Feb 2017 A1
20170127989 Feldman et al. May 2017 A1
20170128009 Pushpala et al. May 2017 A1
20170164881 Fujita et al. Jun 2017 A1
20170251959 Feldman et al. Sep 2017 A1
20170251960 Crouther et al. Sep 2017 A1
20170347925 Wang et al. Dec 2017 A1
20180116572 Simpson et al. May 2018 A1
20180140235 Pushpala et al. May 2018 A1
20180279929 Huang Oct 2018 A1
20180317820 Pace et al. Nov 2018 A1
20180338712 Cass Nov 2018 A1
20190008425 Srinivasan et al. Jan 2019 A1
20190022365 Chowdhury et al. Jan 2019 A1
20190029577 Koelker et al. Jan 2019 A1
20190090811 Reitz et al. Mar 2019 A1
20190091455 Reitz et al. Mar 2019 A1
20190094169 Shah et al. Mar 2019 A1
20190110724 Kamath et al. Apr 2019 A1
20190125223 Wang et al. May 2019 A1
20190167167 Mitchell et al. Jun 2019 A1
20190209095 Kamath et al. Jul 2019 A1
20190223795 Patolsky et al. Jul 2019 A1
20190224712 Petisce et al. Jul 2019 A1
20190241926 Mckinlay et al. Aug 2019 A1
20190261907 Brister et al. Aug 2019 A1
20190274599 Polsky et al. Sep 2019 A1
20190274600 Pesantez et al. Sep 2019 A1
20190298210 Bennet et al. Oct 2019 A1
20190307379 Boock et al. Oct 2019 A1
20190309433 Sattayasamitsathit et al. Oct 2019 A1
20190310219 Boock Oct 2019 A1
20190357827 Li et al. Nov 2019 A1
20200029876 Brister et al. Jan 2020 A1
20200037938 Rong et al. Feb 2020 A1
20200101286 Windmiller et al. Apr 2020 A1
20200121902 Pushpala et al. Apr 2020 A1
20200178853 Pushpala et al. Jun 2020 A1
20200187778 Brister et al. Jun 2020 A1
20200214566 Allen et al. Jul 2020 A1
20200254240 Windmiller et al. Aug 2020 A1
20200297997 Windmiller et al. Sep 2020 A1
20200305771 Feldman et al. Oct 2020 A1
20200359949 Brauker et al. Nov 2020 A1
20200405234 Pushpala et al. Dec 2020 A1
20210045663 Simpson et al. Feb 2021 A1
20210045665 Simpson et al. Feb 2021 A1
20210045666 Simpson et al. Feb 2021 A1
20210100452 Brister et al. Apr 2021 A1
20210100504 Pushpala et al. Apr 2021 A1
20210100505 Pushpala et al. Apr 2021 A1
20210183508 Parker et al. Jun 2021 A1
20210187286 Windmiller et al. Jun 2021 A1
20210190719 LaTour et al. Jun 2021 A1
20210345916 Boock et al. Nov 2021 A1
20210353229 Pierart et al. Nov 2021 A1
20210379370 Windmiller et al. Dec 2021 A1
20210386338 Zhang et al. Dec 2021 A1
20210393201 Morelock et al. Dec 2021 A1
20220031244 Windmiller et al. Feb 2022 A1
20220047190 Taylor et al. Feb 2022 A1
20220054813 Pushpala et al. Feb 2022 A1
20220054814 Pushpala et al. Feb 2022 A1
20220104773 Lee et al. Apr 2022 A1
20220151516 Wang et al. May 2022 A1
20220151518 Pushpala et al. May 2022 A1
20220151519 Pushpala et al. May 2022 A1
20220151558 Pushpala et al. May 2022 A1
20220175278 Campbell et al. Jun 2022 A1
20220175279 Pushpala et al. Jun 2022 A1
20220175282 Hoss et al. Jun 2022 A1
20220214300 Wang et al. Jul 2022 A1
20220225901 Chapman et al. Jul 2022 A1
20220233107 Pushpala et al. Jul 2022 A1
20220249189 Choi et al. Aug 2022 A1
20220298291 Shin et al. Sep 2022 A1
20220322975 Baker et al. Oct 2022 A1
20220322977 Simpson et al. Oct 2022 A1
20220370011 Windmiller et al. Nov 2022 A1
20230074798 Tangney et al. Mar 2023 A1
20230094419 Mansfield, III et al. Mar 2023 A1
20230099617 Mansfield, III et al. Mar 2023 A1
20230137258 Windmiller May 2023 A1
20230190147 Campbell et al. Jun 2023 A1
Foreign Referenced Citations (72)
Number Date Country
101068591 Nov 2007 CN
112617822 Apr 2021 CN
1006868 Jun 2004 EP
1 372 602 Apr 2007 EP
1792565 Oct 2008 EP
1 187 653 Mar 2010 EP
2 898 821 Dec 2017 EP
3 381 370 Oct 2018 EP
H-02-031741 Feb 1990 JP
H-07-275227 Oct 1995 JP
2003-038464 Feb 2003 JP
2003-038465 Feb 2003 JP
2005-087613 Apr 2005 JP
2006-510467 Apr 2005 JP
2005-525141 Aug 2005 JP
2005-322591 Nov 2005 JP
2008-512162 Apr 2008 JP
2008-540013 Nov 2008 JP
10-2016-0108111 Sep 2016 KR
WO-0074763 Dec 2000 WO
WO-0074763 Dec 2000 WO
WO-2006060106 Jun 2006 WO
WO-2006093422 Sep 2006 WO
WO-2006116242 Nov 2006 WO
WO-2006116242 Nov 2006 WO
WO-2007040938 Apr 2007 WO
WO-2009034313 Mar 2009 WO
WO-2009034313 Mar 2009 WO
WO-2009064164 May 2009 WO
WO-2009064164 May 2009 WO
WO-2009124095 Oct 2009 WO
WO-2010014959 Feb 2010 WO
WO-2010014959 Feb 2010 WO
WO-2010022252 Feb 2010 WO
WO-2010022252 Feb 2010 WO
WO-2010045247 Apr 2010 WO
WO-2010059276 May 2010 WO
WO-2010120364 Oct 2010 WO
WO-2010120364 Oct 2010 WO
WO-2011056095 May 2011 WO
WO-2012020332 Feb 2012 WO
WO-2012020332 Feb 2012 WO
WO-2012142625 Oct 2012 WO
WO-2012142625 Oct 2012 WO
WO-2013058879 Apr 2013 WO
WO-2013058879 Apr 2013 WO
WO-2014120114 Aug 2014 WO
WO-2015073459 May 2015 WO
WO-2016189301 Dec 2016 WO
WO-2017129980 Aug 2017 WO
WO-2017189707 Nov 2017 WO
WO-2018017196 Jan 2018 WO
WO-2018071265 Apr 2018 WO
WO-2018164886 Sep 2018 WO
WO-2018170363 Sep 2018 WO
WO-2019156934 Aug 2019 WO
WO-2019222615 Nov 2019 WO
WO-2019239258 Dec 2019 WO
WO-2020023804 Jan 2020 WO
WO-2021015389 Jan 2021 WO
WO-2021025260 Feb 2021 WO
WO-2021086690 May 2021 WO
WO-2021118124 Jun 2021 WO
WO-2021118431 Jun 2021 WO
WO-2022026764 Feb 2022 WO
WO-2022066985 Mar 2022 WO
WO-2022066992 Mar 2022 WO
WO-2022090741 May 2022 WO
WO-2022136785 Jun 2022 WO
WO-2023055755 Apr 2023 WO
WO-2023064877 Apr 2023 WO
WO-2023133468 Jul 2023 WO
Non-Patent Literature Citations (114)
Entry
Abbot press release (2020). “New late-breaking data show use of abbott's Freestyle® Libre System significantly reduces HBA1C levels in people with type 2 diabetes using insulin or not,” 3 pages.
American Diabetes Association® Press Release (2020). “American Diabetes Association® Applauds policymakers' Focus on Addressing High Costs of Insulin for Seven Million Americans,” 4 pages.
Bantle, J.P. et al. (1997). “Glucose measurement in patients with diabetes mellitus with dermal interstitial fluid,” J. Lab. Clin. Med. 130:436-441.
Beckles, G.L. et al. (2016). “Disparities in the prevalence of diagnosed diabetes—United States, 1999-2002 and 2011-2014,” MMWR 65:1265-1269.
Cao, J. et al. (2017). “Validation of capillary blood analysis and capillary testing mode on the epoc Point of Care system,” Pract. Lab. Med. 9:24-27.
Castle, J.R. et al. (2012). “The accuracy benefit of multiple amperometric glucose sensors in people with type 1 diabetes,” Diabetes Care 35:706-710.
Chang, H. et al. (2017). “A swellable microneedle patch to rapidly extract skin interstitial fluid for timely metabolic analysis,” Adv. Mater. 29:1702243.
Dexcom (2020). Analyst Day Presentation, 27 total pages.
Dexcom (2020). Analyst Day Presentation, 19 total pages.
Diabetes Care (2021). “7. Diabetes Technology: Standards of Medical Care in Diabetes—2021,” Diabetes Care 44(Supplement 1):S85-S99.
Donnelly, R.F. et al. (2007). “Microstructured Devices for Transdermal Drug Delivery and Minimally-Invasive Patient Monitoring,” Recent Patents on Drug Delivery & Formulation 1:195-200.
Extended European Search Report dated May 8, 2015, for EP Application No. 12 842 020.5, filed on Aug. 31, 2012, 7 pages.
Extended European Search Report dated Oct. 27, 2022, for EP Application No. 21 850 331.6, filed on Jul. 29, 2021, 8 pages.
Fang, M. et al. (2021). “Trends in Diabetes Treatment and Control in U.S. Adults, 1999-2018,” N. Engl. Med. 384:2219-2228.
Final Office Action dated Aug. 19, 2016, for U.S. Appl. No. 14/965,755, filed Dec. 10, 2015, 17 pages.
Final Office Action dated Nov. 28, 2016, for U.S. Appl. No. 14/342,536, filed Jul. 30, 2014, 34 pages.
Final Office Action dated May 18, 2018, for U.S. Appl. No. 15/687,145, filed Aug. 25, 2017, 23 pages.
Final Office Action dated Dec. 7, 2020, for U.S. Appl. No. 15/961,793, filed Apr. 24, 2018, 13 pages.
Final Office Action dated May 21, 2021, for U.S. Appl. No. 16/051,398, filed Jul. 31, 2018, 11 pages.
Final Office Action dated Jun. 9, 2021, for U.S. Appl. No. 16/169,939, filed Oct. 24, 2018, 24 pages.
Final Office Action dated Sep. 23, 2021, for U.S. Appl. No. 15/913,709, filed Mar. 6, 2018, 17 pages.
Final Office Action dated May 9, 2022, for U.S. Appl. No. 17/389,153, filed Jul. 29, 2021, 17 pages.
Final Office Action dated Aug. 15, 2022, for U.S. Appl. No. 16/051,398, filed Jul. 31, 2018, 15 pages.
Final Office Action dated Oct. 27, 2022, for U.S. Appl. No. 15/913,709, filed Mar. 6, 2018, 21 pages.
French, D.P. et al. (2008). “Original Article: Psychological Care Self-monitoring of blood glucose changed non-insulin-treated Type 2 diabetes patients' beliefs about diabetes and self-monitoring in a randomized trial,” Diav. Med. 25:1218-1228.
Gittard, S.D. et al. (2009). “Fabrication of Polymer Microneedles Using a Two-Photon Polymerization and Micromolding Process,” J. Diabetes Sci. Technol. 3:304-311.
Grady, M. et al. (2017). “Examining the Impact of a Novel Blood Glucose Monitor With Color Range Indicator on Decision-Making in Patients With Type 1 and Type 2 Diabetes and its Association With Patient Numeracy Level,” JMIR Diabetes 2:e24.
Grady, M. et al. (2018). “Use of Blood Glucose Meters Featuring Color Range Indicators Improves Glycemic Control in Patients with Diabetes in Comparison to Blood Glucose Meters Without Color (ACCENTS Study),” J. Diab. Sci. Tech. 12:1211-1219.
Groenendaal, W. et al. (2008). “Modeling Glucose and Water Dynamics in Human Skin,” Diab. Tech. Therap. 10:283-293.
International Search Report dated Dec. 30, 2021, for PCT Application No. PCT/US2021/043786, filed on Jul. 29, 2021, 7 pages.
International Search Report dated Sep. 10, 2020, for PCT Application No. PCT/US2020/037379, filed on Jun. 12, 2020, 2 pages.
International Search Report dated Feb. 4, 2021, for PCT Application No. PCT/US2020/056517, filed on Oct. 20, 2020, 2 pages.
International Search Report dated Sep. 30, 2021, for PCT Application No. PCT/US2021/040385, filed on Jul. 2, 2021, 2 pages.
International Search Report dated Aug. 29, 2022, for PCT Application No. PCT/US2022/028196, filed on May 6, 2022, 2 pages.
International Search Report dated Jun. 27, 2013, for PCT Application No. PCT/US2012/053544, filed on Aug. 31, 2012, 4 pages.
Jeon, G. et al. (2011). “Electrically Actuatable Smart Nanoporous Membrane for Pulsatile Drug Release,” Nano Lett. 11:1284-1288.
Jina, A et al. (2014). “Design, development, and evaluation of a novel microneedle array-based continuous glucose monitor,” J. Diabetes Sci. Technol. 8:483-487.
Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group (2008). “Continuous Glucose Monitoring and Intensive Treatment of Type 1 Diabetes,” N. Engl. Med. 359:1464-1476.
Karter, A.J. et al. (2021). “Association of Real-time Continuous Glucose Monitoring with Glycemic Control and Acute Metabolic Events Among Patients with Insulin-Treated Diabetes,” JAMA 325:2273-2284.
Lhernould, M.S. et al. (2015). “Review of Patents for Microneedle Application Devices Allowing Fluid Injections Through the Skin,” Recent Patents on Drug Delivery & Formulation 9:146-157.
Malitesta et al. (1990). “Glucose fast-response amperometric sensor based on glucose oxidase immobilized in an electropolymerized poly(o-phenylenediamine) film,” Anal. Chem. 62:2735-2740.
Martens, T. et al. (2021). “Effect of Continuous Glucose Monitoring on Glycemic Control in Patients with Type 2 Diabetes Treated with Basal Insulin a Randomized Clinical Trial,” JAMA 325:2262-2272.
Mcclatchey, P.M. et al. (2019). “Fibrotic Encapsulation Is the Dominant Source of Continuous Glucose Monitor Delays,” Diabetes 68:1892-1901.
Miller, P.R. et al. (2011). “Integrated carbon fiber electrodes within hollow polymer microneedles for transdermal electrochemical sensing,” BioMicrofluidics 5(1):013415.
Mohan, A.M. (2017). “Continuous minimally-invasive alcohol monitoring using microneedle sensor arrays,” Biosensors and Bioelectronics 91:574-579.
Neerken, S. et al. (2004). “Characterization of age-related effects in human skin: A comparative study that applies confocal laser scanning microscopy and optical coherence tomography,” J. Biomed. Optics 9:274-281.
Non-Final Office Action dated Mar. 10, 2016, for U.S. Appl. No. 14/965,755, filed Dec. 10, 2015, 15 pages.
Non-Final Office Action dated Mar. 30, 2016, for U.S. Appl. No. 14/342,536, filed Jul. 30, 2014, 31 pages.
Non-Final Office Action dated Mar. 9, 2017, for U.S. Appl. No. 14/965,755, filed Dec. 10, 2015, 17 pages.
Non-Final Office Action dated Apr. 6, 2017, for U.S. Appl. No. 14/342,536, filed Jul. 30, 2014, 32 pages.
Non-Final Office Action dated Nov. 1, 2017, for U.S. Appl. No. 15/687,145, filed Aug. 25, 2017, 19 pages.
Non-Final Office Action dated Jan. 19, 2018, for U.S. Appl. No. 14/843,926, filed Sep. 2, 2015, 11 pages.
Non-Final Office Action dated Apr. 13, 2020, for U.S. Appl. No. 15/961,793, filed Apr. 24, 2018, 13 pages.
Non-Final Office Action dated Sep. 3, 2020, for U.S. Appl. No. 16/169,939, filed Oct. 24, 2018, 19 pages.
Non-Final Office Action dated Sep. 16, 2020, for U.S. Appl. No. 15/913,709, filed Mar. 6, 2018, 15 pages.
Non-Final Office Action dated Oct. 16, 2020, for U.S. Appl. No. 16/051,398, filed Jul. 31, 2018, 13 pages.
Non-Final Office Action dated Nov. 4, 2021, for U.S. Appl. No. 16/169,939, filed Oct. 24, 2018, 20 pages.
Non-Final Office Action dated Nov. 26, 2021, for U.S. Appl. No. 16/051,398, filed Jul. 31, 2018, 15 pages.
Non-Final Office Action dated Nov. 29, 2021, for U.S. Appl. No. 17/389,153, filed Jul. 29, 2021, 14 pages.
Non-Final Office Action dated Apr. 8, 2022, for U.S. Appl. No. 17/650,056, filed Feb. 4, 2022, 14 pages.
Non-Final Office Action dated May 13, 2022, for U.S. Appl. No. 15/913,709, filed Mar. 6, 2018, 20 pages.
Non-Final Office Action dated Dec. 21, 2022, for U.S. Appl. No. 16/051,398, filed Jul. 31, 2018, 12 pages.
Non-Final Office Action dated Jan. 27, 2023, for U.S. Appl. No. 17/971,415, filed Oct. 21, 2022, 15 pages.
Non-Final Office Action dated Feb. 16, 2023, for U.S. Appl. No. 17/738,990, filed May 6, 2022, 8 pages.
Notice of Allowance dated Jul. 6, 2017, for U.S. Appl. No. 14/965,755, filed Dec. 10, 2015, 12 pages.
Notice of Allowance dated Jul. 12, 2017, for U.S. Appl. No. 14/342,536, filed Jul. 30, 2014, 14 pages.
Notice of Allowance dated Feb. 13, 2018, for U.S. Appl. No. 14/843,926, filed Sep. 2, 2015, 8 pages.
Notice of Allowance dated Aug. 24, 2018, for U.S. Appl. No. 15/687,145, filed Aug. 25, 2017, 7 pages.
Notice of Allowance dated May 25, 2021, for U.S. Appl. No. 15/961,793, filed Apr. 24, 2018, 11 pages.
Notice of Allowance dated Sep. 12, 2022, for U.S. Appl. No. 17/389,153, filed Jul. 29, 2021, 8 pages.
Polonsky, W.H. et al. (2011). “A survey of blood glucose monitoring in patients with type 2 diabetes: Are recommendations from health care professionals being followed?” Curr. Med. Res. & Opinion 27:31-37.
Rigla, M. et al. (2018). “Human Subcutaneous Tissue Response to Glucose Sensors: Macrophages Accumulation Impact on Sensor Accuracy,” Diabetes Technology & Therapeutics 20:296-302.
Sachdeva, V. et al. (2011). “Microneedles and their applications,” Recent Patents on Drug Delivery & Formulation 5:95-132.
Sheikh, Z. et al. (2015). “Macrophages, Foreign Body Giant Cells and Their Response to Implantable Biomaterials,” Materials 8:5671-5701.
Shi, T. et al. (2016). “Modeling and Measurement of Correlation between Blood and Interstitial Glucose Changes,” J. Diab. Res. vol. 2016, 9 pages.
Singh, T.R.R. et al. (2010). “Microporation techniques for enhanced delivery of therapeutic agents,” Recent Patents on Drug Delivery & Formulation 4:1-17.
Swedish Search Report dated Feb. 3, 2023 for SE Application No. 2350067-1, 7 pages.
Texas Instruments (Sep. 2007). Data sheet for a LMP2234 quad micropower, 1.6V, precision, operational amplifier with CMOS input, Sep. 2007, revised Mar. 2013, 31 total pages.
Windmiller, J.R. (2012). “Molecular scale biocomputing: An enzyme logic approach,” University of California, San Diego, A dissertation submitted in partial satisfaction of the requirements for the degree Doctor of Philosophy in Electrical Engineering (Photonics), 78 total pages.
Windmiller, J.R. et al. (2011). “Bicomponent microneedle array biosensor for minimally-invasive glutamate monitoring,” Electroanalysis 23:2302-2309.
Windmiller, J.R. et al. (2011). “Microneedle array-based carbon paste amperometric sensors and biosensors,” Analyst 136:1846-1851.
Written Opinion of the International Searching Authority dated Dec. 30, 2021, for PCT Application No. PCT/US2021/043786, filed on Jul. 29, 2021, 10 pages.
Written Opinion of the International Searching Authority dated Sep. 10, 2020, for PCT Application No. PCT/US2020/037379, filed on Jun. 12, 2020, 4 pages.
Written Opinion of the International Searching Authority dated Feb. 4, 2021, for PCT Application No. PCT/US2020/056517, filed on Oct. 20, 2020, 5 pages.
Written Opinion of the International Searching Authority dated Sep. 30, 2021, for PCT Application No. PCT/US2021/040385, filed on Jul. 2, 2021, 2 pages.
Written Opinion of the International Searching Authority dated Aug. 29, 2022, for PCT Application No. PCT/US2022/028196, filed on May 6, 2022, 5 pages.
Written Opinion of the International Searching Authority dated Jun. 27, 2013, for PCT Application No. PCT/US2012/053544, filed on Aug. 31, 2012, 15 pages.
Yoon, Y. et al. (2013). “Fabrication of a Microneedle/CNT Hierarchical Micro/Nano Surface Electrochemical Sensor and Its In-Vitro Glucose Sensing Characterization,” Sensors 13:16672-16681.
Al Hayek et al., “Patient Satisfaction and Clinical Efficacy of Novel Blood Glucose Meters Featuring Color Range Indicators in Patients With Type 2 Diabetes: A Prospective Study” Cureus Oct. 27, 2020; 12(10):e11195. doi: 10.7759/cureus.11195.
Allen et al., “Continuous glucose monitoring counseling improves physical activity behaviors of individuals with type 2 diabetes: A randomized clinical trial” Diabetes Res Clin Pract. Jun. 2008; 80(3): 371-379. doi:10.1016/j.diabres.2008.01.006.
Barrett et al., “Risk for Newly Diagnosed Diabetes 30 Days After SARS-COV-2 Infection Among Persons Aged 18 Years—United States, Mar. 1, 2020-Jun. 28, 2021” MMWR Morb Mortal Wkly Rep. Jan. 14, 2022; 71(2):59-65. doi: 10.15585/mmwr.mm7102e2.
Brown, C., “Design of Electronics for Wearable Electrochemical Sensors”, University of California, San Diego, 2019, 39 pgs.
Centers for Disease Control, “National Diabetes Statistics Report 2020 Estimates of Diabetes and Its Burden in the United States” (2020) 32 pages.
Dunkin et al., “Scarring occurs at a critical depth of skin injury: precise measurement in a graduated dermal scratch in human volunteers” Plast Reconstr Surg. May 2007; 119(6):1722-1732. doi: 10.1097/01.prs.0000258829.07399.f0.
Ehrhardt et al, “Behavior Modification in Prediabetes and Diabetes: Potential Use of Real-Time Continuous Glucose Monitoring” Journal of Diabetes Science and Technology Mar. 2019; 13(2):271-275.
Ehrhardt et al., “Continuous Glucose Monitoring As a Behavior Modification Tool” Clin Diabetes. Apr. 2020; 38(2):126-131. doi: 10.2337/cd19-0037.
Ehrhardt et al, “The Effect of Real-Time Continuous Glucose Monitoring on Glycemic Control in Patients with Type 2 Diabetes Mellitus” Journal of Diabetes Science and Technology May 2011; 5(3):668-675.
Extended European Search Report dated Mar. 30, 2023, for European Application No. EP20881425.1, 8 pages.
Fonda et al., “The Cost-Effectiveness of Real-Time Continuous Glucose Monitoring (RT-CGM) in Type 2 Diabetes” Journal of Diabetes Science and Technology (2016) 10(4):898-904.
Han et al., “The End of the Road for the YSI 2300 Analyzer: Where Do We Go Now?” Journal of Diabetes Science and Technology (2020) 14(3):595-600.
Han et al., “The YSI 2300 Analyzer Replacement Meeting Report” Journal of Diabetes Science and Technology (2020) 14(3):679-686.
Non-Final Office Action dated Mar. 9, 2023 for U.S. Appl. No. 17/389,156, filed Jul. 29, 2021, 24 pages.
Non-Final Office Action dated May 2, 2023 for U.S. Appl. No. 15/913,709, filed Mar. 6, 2018, 18 pages.
Non-Final Office Action dated May 24, 2023 for U.S. Appl. No. 18/086,543, filed Dec. 21, 2022, 19 pages.
Non-Final Office Action dated Jun. 2, 2023, for U.S. Appl. No. 17/367,274, filed Jul. 2, 2021, 27 pages.
Non-Final Office Action dated Jun. 20, 2023, for U.S. Appl. No. 17/073,331, filed Oct. 17, 2020, 10 pages.
Notice of Allowance dated Jun. 12, 2023, for U.S. Appl. No. 17/971,415, filed Oct. 21, 2022, 14 pages.
Notice of Allowance dated Jun. 12, 2023, for U.S. Appl. No. 17/738,990, filed May 6, 2022, 7 pages.
Sharifi et al., “Redundancy in Glucose Sensing: Enhanced Accuracy and Reliability of an Electrochemical Redundant Sensor for Continuous Glucose Monitoring” Journal of Diabetes Science and Technology (2016) 10(3):669-678.
Turner et al., “Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)” The Lancet Sep. 1998; 352(9131):837-853.
Vigersky et al., “Short- and Long-Term Effects of Real-Time Continuous Glucose Monitoring in Patients with Type 2 Diabetes” Diabetes Care Jan. 2012; 35:32-38.
Wolicki et al., “Epidemiology and Prevention of Vaccine-Preventable Diseases: Chapter 6: Vaccine Administration” Centers for Disease Control and Prevention (2021) 17 pages.
World Health Organization, “Diabetes”, Sep. 16, 2022, 5 pages.
Young et al., “Glucose Self-monitoring in Non-Insulin-Treated Patients With Type 2 Diabetes in Primary Care Settings: A Randomized Trial” JAMA Intern Med. Jul. 2017; 177(7):920-929.
Provisional Applications (1)
Number Date Country
62492142 Apr 2017 US
Continuations (1)
Number Date Country
Parent 15961793 Apr 2018 US
Child 17349234 US